Nanobac Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Nanobac Pharmaceuticals Incorporated
NNBP Stock  USD 0.0001  0.00  0.000003%   
Nanobac Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Nanobac Pharmaceuticals Incorporated investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Nanobac Pharmaceuticals financial statements helps investors assess Nanobac Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nanobac Pharmaceuticals' valuation are summarized below:
Gross Profit
3.1 K
Market Capitalization
124.8 K
Enterprise Value Revenue
7.0798
Revenue
17.6 K
Quarterly Revenue Growth
0.866
There are currently one hundred twenty fundamental ratios for Nanobac Pharmaceuticals that can be evaluated and compared over time across peers in the industry. Investors and active traders are advised to check Nanobac Pharmaceuticals' last-minute fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 03/19/2025, Market Cap is likely to drop to about 15.6 M. In addition to that, Enterprise Value is likely to drop to about 19 M

Nanobac Pharmaceuticals Total Revenue

15,065.95

Check Nanobac Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nanobac Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.6 M or Total Revenue of 15.1 K, as well as many indicators such as Price To Sales Ratio of 90.9, Days Sales Outstanding of 56.52 or Invested Capital of 0.0. Nanobac financial statements analysis is a perfect complement when working with Nanobac Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Nanobac Pharmaceuticals Correlation against competitors.

Nanobac Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets7.7 M8.3 M6.9 M
Slightly volatile
Other Current Liabilities1.1 M1 M846.1 K
Slightly volatile
Total Current Liabilities4.6 M7.8 M6.3 M
Slightly volatile
Accounts Payable616.8 K1.1 M922.1 K
Pretty Stable
Total Liabilities7 M11 M8.9 M
Slightly volatile
Common Stock14.3 M26.3 M21.2 M
Slightly volatile
Cash3.4 K3.5 K6.8 K
Slightly volatile
Other Assets7.7 K8.1 K12.7 K
Slightly volatile
Good Will3.2 M3.3 M3.7 M
Slightly volatile
Inventory8.8 K9.3 K10.5 K
Slightly volatile
Other Current Assets18.9 K13.5 K15.1 K
Pretty Stable
Preferred Stock Total Equity280 K315 K343.4 K
Slightly volatile
Intangible Assets4.2 M3.2 M3.8 M
Slightly volatile
Property Plant Equipment32.1 K33.8 K43 K
Slightly volatile
Other Liabilities3 M3.3 M2.8 M
Slightly volatile
Net Receivables1.9 K1.7 K2 K
Slightly volatile
Short and Long Term Debt3.4 M4.7 M3.9 M
Slightly volatile
Total Current Assets26.3 K27.7 K35.6 K
Slightly volatile
Short Term Debt3.4 M4.7 M3.9 M
Slightly volatile
Long Term Debt2.3 M2.6 M2.8 M
Slightly volatile

Nanobac Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative2.6 M3.3 M2.8 M
Slightly volatile
Total Revenue15.1 K15.9 K17 K
Pretty Stable
Gross Profit3.4 K3.6 K3.5 K
Slightly volatile
Cost Of Revenue12.4 K13.1 K13.6 K
Slightly volatile
Research Development1.6 M1.3 M1.1 M
Slightly volatile
Total Operating Expenses4.1 M4 M4.6 M
Slightly volatile
Other Operating Expenses469.7 K414.3 K476.7 K
Slightly volatile
Non Recurring468 K526.5 K574 K
Slightly volatile

Nanobac Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities995.1 K1 M934.6 K
Very volatile
Change To Liabilities632.9 K602.7 K643 K
Slightly volatile
Change To Inventory67.7 K64.5 K58 K
Pretty Stable
Total Cashflows From Investing Activities56.8 K43.7 K58.1 K
Slightly volatile
Other Cashflows From Investing Activities55.1 K45.1 K65.5 K
Slightly volatile
Sale Purchase Of Stock171 K180 K264.1 K
Slightly volatile
Net Borrowings1.6 M819.8 K1 M
Pretty Stable
Depreciation495.7 K414.3 K475.7 K
Slightly volatile
Change To Operating Activities1.2 M1.2 M1 M
Slightly volatile
Change To Netincome2.5 M4 M3.4 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio90.995.6998.0548
Slightly volatile
Days Sales Outstanding56.5244.5241.4697
Very volatile
Average Payables394.7 K415.5 K454.2 K
Slightly volatile
Capex To Depreciation0.00360.00380.0448
Slightly volatile
EV To Sales239210218
Slightly volatile
Inventory Turnover1.541.621.4378
Slightly volatile
Days Of Inventory On Hand168233250
Slightly volatile
Payables Turnover0.01470.01550.2128
Slightly volatile
Average Inventory41.9 K44.1 K126.9 K
Slightly volatile
Research And Ddevelopement To Revenue61.6458.760.5877
Slightly volatile
Capex To Revenue0.07880.10.0886
Slightly volatile
Cash Per Share2.0E-42.0E-40.0103
Slightly volatile
Days Payables Outstanding25.6 K24.4 K25.2 K
Slightly volatile
Income Quality0.190.120.1554
Slightly volatile
ROE2.632.512.5862
Slightly volatile
Intangibles To Total Assets0.570.890.8993
Pretty Stable
Current Ratio0.0050.00520.1189
Slightly volatile
Receivables Turnover8.068.499.0801
Pretty Stable
Capex Per Share1.0E-41.0E-40.077
Slightly volatile
Average Receivables1.4 K1.5 K132.2 K
Slightly volatile
Revenue Per Share0.00120.00130.8614
Slightly volatile
Interest Debt Per Share0.02940.0310.634
Slightly volatile
Debt To Assets0.660.57090.5803
Slightly volatile
Operating Cycle281268280
Slightly volatile
Days Of Payables Outstanding25.6 K24.4 K25.2 K
Slightly volatile
Operating Profit Margin264251259
Slightly volatile
Total Debt To Capitalization2.212.112.2117
Slightly volatile
Return On Capital Employed9.799.339.6214
Slightly volatile
Ebit Per Revenue264251259
Slightly volatile
Quick Ratio0.00330.00350.1175
Slightly volatile
Net Income Per E B T0.840.910.9778
Very volatile
Cash Ratio6.0E-47.0E-40.0787
Slightly volatile
Days Of Inventory Outstanding168233250
Slightly volatile
Days Of Sales Outstanding56.5244.5241.4697
Very volatile
Free Cash Flow Operating Cash Flow Ratio0.720.90.9419
Pretty Stable
Fixed Asset Turnover0.40.420.5053
Slightly volatile
Debt Ratio0.660.57090.5803
Slightly volatile
Price Sales Ratio90.995.6998.0548
Slightly volatile
Asset Turnover0.00270.00280.0415
Slightly volatile
Gross Profit Margin0.150.160.1979
Slightly volatile
Return On Equity2.632.512.5862
Slightly volatile

Nanobac Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap15.6 M21.5 M21.8 M
Pretty Stable
Enterprise Value19 M26.3 M27.1 M
Pretty Stable

About Nanobac Pharmaceuticals Financial Statements

Nanobac Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Nanobac Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Nanobac Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Nanobac Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue15.9 K15.1 K
Cost Of Revenue13.1 K12.4 K
Research And Ddevelopement To Revenue 58.70  61.64 
Capex To Revenue 0.10  0.08 
Ebit Per Revenue 251.03  263.58 

Additional Tools for Nanobac Stock Analysis

When running Nanobac Pharmaceuticals' price analysis, check to measure Nanobac Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobac Pharmaceuticals is operating at the current time. Most of Nanobac Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Nanobac Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobac Pharmaceuticals' price. Additionally, you may evaluate how the addition of Nanobac Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY